NEW YORK (GenomeWeb News) – Hybrigenics said today that it has signed a co-marketing agreement with Dualsystems Biotech covering yeast two-hybrid screening services for full membrane proteins.
Under the terms of the agreement, both Dualsystems and Hybrigenics will commercialize Dualsystems’ DUALmembrane screens, which were designed for identifying protein interactions involving full membrane proteins.
Hybrigenics will perform the screens on its ISO 9001-certified yeast two-hybrid platform.
The companies said that the profit-sharing partnership will “boost Dualsystems' commercial and production volumes for its membrane technology.”
Hybrigenics is a biopharmaceutical company focused on developing cancer therapies through its Hybrigenics Pharma unit. The company also offers a range of protein-interaction screening services.